Previous Close | 12.35 |
Open | 12.35 |
Bid | 12.87 x 300 |
Ask | 12.98 x 100 |
Day's Range | 12.31 - 12.91 |
52 Week Range | 9.02 - 26.35 |
Volume | |
Avg. Volume | 1,142,424 |
Market Cap | 621.801M |
Beta (5Y Monthly) | 2.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be presented at a satellite symposium at the EULAR 2024 Congress in June – – Evaluating CABA-201 without preconditioning by initiation of the RESET-PV™ sub-study within the ongoing DesCAARTes™ trial in pemphigus vulga
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY. A live webcast of the presentation wi
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24 – – RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24 – – Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile derma